Cybin Secures European Patent for CY003
Ticker: HELP · Form: 6-K · Filed: Jun 3, 2025 · CIK: 1833141
Sentiment: bullish
Topics: patent, pharmaceuticals, mental-health, drug-development
TL;DR
Cybin got a European patent for its CY003 drug for alcohol use disorder. Big win for IP.
AI Summary
On June 3, 2025, Cybin Inc. filed a Form 6-K report. This filing includes a news release dated June 3, 2025, announcing additional patent protection for its deuterated psilocybin product candidate, CY003. The patent, granted by the European Patent Office, covers CY003 for the treatment of alcohol use disorder.
Why It Matters
This patent grant strengthens Cybin's intellectual property portfolio for its novel psilocybin-based therapy, potentially enhancing its market exclusivity and commercial prospects for treating alcohol use disorder.
Risk Assessment
Risk Level: medium — The company operates in the highly regulated and speculative biotechnology sector, with clinical trial outcomes and regulatory approvals being key risk factors.
Key Players & Entities
- Cybin Inc. (company) — Registrant
- June 3, 2025 (date) — Filing and News Release Date
- CY003 (product) — Deuterated psilocybin product candidate
- European Patent Office (company) — Granting body for the patent
- alcohol use disorder (medical_condition) — Indication for CY003
- Doug Drysdale (person) — Chief Executive Officer
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a news release dated June 3, 2025, announcing additional patent protection for Cybin Inc.'s product candidate CY003.
What specific drug candidate is mentioned in the news release?
The news release mentions the deuterated psilocybin product candidate, CY003.
Which regulatory body granted the patent for CY003?
The European Patent Office granted the patent for CY003.
What condition is CY003 intended to treat according to the patent?
According to the patent, CY003 is intended for the treatment of alcohol use disorder.
Who signed the Form 6-K on behalf of Cybin Inc.?
Doug Drysdale, Chief Executive Officer, signed the Form 6-K on behalf of Cybin Inc.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 3, 2025 by Doug Drysdale regarding CYBIN INC. (HELP).